Eric J. Devroe
Chief Operating OfficerDr. Eric J. Devroe, Ph.D., has been the Chief Operating Officer at Acrivon Therapeutics, Inc. since August 2022. He serves as a Director of Opsonix, Inc. He served as Senior Vice President of Business Operations at Acrivon Therapeutics, Inc since October 2020 until August 2022. Dr. Devroe is an executive and entrepreneur with significant experience helping found, launch and build new life science companies. Dr. Devroe served as an Executive Director of Strategic Planning & Business Development of Metamark Genetics, Inc. Dr. Devroe joined Metamark with extensive experience in new venture formation, strategic positioning and technology instantiation and execution across leading edge fields in the life sciences. Prior to Metamark, Dr. Devroe was a Venture Associate at Flagship Ventures where he focused on conceptualizing and launching new companies in the bioenergy and therapeutics space. Previously Dr. Devroe was an Associate Director in charge of gene synthesis at Codon Devices. Earlier in his career he served as Vice President of Business & Strategy Development at Metamark Genetics, Inc. and an Associate at Flagship Pioneering. Prior to Codon, he was a Senior Scientist at Ambion/Asuragen, where he developed and launched the first commercially available qRT-PCR assay for microRNA detection. He also focused on miRNA diagnostics and therapeutic applications of synthetic microRNA precursor and inhibitor molecules in cancer. During his graduate work, he identified and investigated novel HIV-1 interacting proteins. He also developed and described the first retroviral vector for delivery of small hairpin RNA (shRNA) and was a thought leader on the therapeutic application of siRNA. Most recently, he was Founder and Chief Executive Officer of Xione Therapeutics, Inc. Prior to Xione, he was the Founder and Chief Executive Officer of Opsonix, Inc. Prior to Opsonix, he served as Executive Director of Strategic Alliances at MD Anderson Cancer Center Dr. Devroe is the author of twelve publications and over twenty utility and provisional patent applications in the areas of HIV-1, synthetic biology, siRNA, miRNA, kinase biology and cancer therapeutics. Dr. Devroe received his Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard Medical School, Harvard University and was the recipient of a Howard Hughes Medical Institute Predoctoral Fellowship. He holds a B.S. in Microbiology from the University of Texas at Austin.
Positions
- Company NameAcrivon Therapeutics, Inc.Stock CodeACRVPositionChief Operating OfficerColleagues
- PBPeter Blume-JensenCo-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer
- KMKristina MassonCo-Founder, Executive VP of Business Operations, Site Head, Treasurer & Director
- ADAdam D. LevyCFO & Principal Financial Officer
- KPKatharine PetersonVice President of Finance & Accounting
- JVJesper V. OlsenAcademic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board
- MJMichael John TomsicekIndependent Director
- CMCharles M. BaumIndependent Director
